All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Impact of mutated JAK2 allele burden on the outcomes in PV and ET
Bookmark this article
|
A prospective study which measured changes in JAK2 and CALR variant allele frequency (VAF) in patients with polycythemia vera (PV) and essential thrombocythemia (ET) treated with ruxolitinib has been published in the American Journal of Hematology by Guglielmelli et al.1 Changes in mutant VAF were measured alongside complete clinical and hematological response (CCHR) and other clinical outcomes to establish whether a correlation exists between mutated JAK2 allele burden and clinical outcomes. |
| Key learnings |
| Overall, the median JAK2 VAF reduced from 68% to 3.5% over the study period. |
| A durable molecular response (DMR) defined as a stable VAF ≤2% for ≥1 year was observed in 20% of patients, a partial MR (PMR) in 25%, and a lack of MR in 56% of patients. |
| CCHR was reported in 69% of patients and was independent of the degree of molecular response. |
| Increased DMR was correlated with longer duration of CCHR, reduced progression to myelofibrosis, and increased rates of myelofibrosis-free, event-free, and progression-free survival. |
| Factors predicting DMR and reduced progression to myelofibrosis included a baseline JAK2 VAF <50% and a VAF reduction ≥35% after 2 years of treatment. |
| The findings underscore the significance of targeted molecular response in managing myeloproliferative neoplasms, advocating for personalized treatment strategies based on JAK2 VAF dynamics. |
- Guglielmelli P, Mora B, Gesullo F, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99(8):1550-1559. DOI: 1002/ajh.27400
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox